Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Activator or inhibitor? GSK-3 as a new drug target.

Takahashi-Yanaga F.

Biochem Pharmacol. 2013 Jul 15;86(2):191-9. doi: 10.1016/j.bcp.2013.04.022. Epub 2013 May 2. Review.

PMID:
23643839
2.

[A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].

Liu SN, Shen ZF.

Yao Xue Xue Bao. 2007 Dec;42(12):1227-31. Review. Chinese.

PMID:
18338632
4.

Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.

Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox L, Mills D, Brown MJ, Haigh D, Ward RW, Smith DG, Murray KJ, Reith AD, Holder JC.

Chem Biol. 2000 Oct;7(10):793-803.

5.

Pharmacological inhibitors of glycogen synthase kinase 3.

Meijer L, Flajolet M, Greengard P.

Trends Pharmacol Sci. 2004 Sep;25(9):471-80. Review.

PMID:
15559249
6.

Inhibition of glycogen synthase kinase-3.

Ougolkov AV, Billadeau DD.

Methods Mol Biol. 2008;468:67-75. doi: 10.1007/978-1-59745-249-6_5.

PMID:
19099246
7.

Glycogen synthase kinase 3 as an anticancer drug target: novel experimental findings and trends in the design of inhibitors.

Osolodkin DI, Palyulin VA, Zefirov NS.

Curr Pharm Des. 2013;19(4):665-79. Review.

PMID:
23016861
8.

Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease.

Golpich M, Amini E, Hemmati F, Ibrahim NM, Rahmani B, Mohamed Z, Raymond AA, Dargahi L, Ghasemi R, Ahmadiani A.

Pharmacol Res. 2015 Jul;97:16-26. doi: 10.1016/j.phrs.2015.03.010. Epub 2015 Mar 28. Review.

PMID:
25829335
9.
10.
11.

Glycogen synthase kinase-3 as drug target: from wallflower to center of attention.

Van Wauwe J, Haefner B.

Drug News Perspect. 2003 Nov;16(9):557-65. Review.

PMID:
14702136
12.

GSK-3 inhibitors and insulin receptor signaling in health, disease, and therapeutics.

Wada A.

Front Biosci (Landmark Ed). 2009 Jan 1;14:1558-70. Review.

PMID:
19273146
13.
14.

Glycogen synthase kinase-3--an overview of an over-achieving protein kinase.

Kockeritz L, Doble B, Patel S, Woodgett JR.

Curr Drug Targets. 2006 Nov;7(11):1377-88. Review.

PMID:
17100578
15.

Glycogen synthase kinase 3 in Wnt signaling pathway and cancer.

Tejeda-Muñoz N, Robles-Flores M.

IUBMB Life. 2015 Dec;67(12):914-22. doi: 10.1002/iub.1454. Epub 2015 Nov 24. Review.

16.

Pancreastatin, a chromogranin-A-derived peptide, inhibits insulin-stimulated glycogen synthesis by activating GSK-3 in rat adipocytes.

González-Yanes C, Sánchez-Margalet V.

Biochem Biophys Res Commun. 2001 Nov 23;289(1):282-7.

PMID:
11708813
17.

Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes.

Henriksen EJ, Dokken BB.

Curr Drug Targets. 2006 Nov;7(11):1435-41. Review.

PMID:
17100583
18.
19.
20.

Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways.

Manoukian AS, Woodgett JR.

Adv Cancer Res. 2002;84:203-29. Review.

PMID:
11883528

Supplemental Content

Support Center